Article ID Journal Published Year Pages File Type
8744812 Clinical Microbiology and Infection 2018 11 Pages PDF
Abstract
Metronidazole is mentioned in the ESCMID guideline as first-line therapy, but we propose that oral vancomycin will become the first choice when antibiotic treatment for CDI is necessary. Fidaxomicin is a good alternative, especially in patients at risk of relapse. Vancomycin combined with faecal microbiota transplantation remains the primary therapy for multiple recurrent CDI. We anticipate that new medication that protects the gut microbiota will be further developed and tested to prevent CDI during antibiotic therapy.
Related Topics
Life Sciences Immunology and Microbiology Microbiology
Authors
, , , , , , , ,